Telormedix, a Swiss clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, has appointed Nicholas Ralphe Rogerson as chairman.
Rogerson has worked in the pharmaceutical industry for nearly 25 years in major companies, as well as in consulting and investment banking. He specialises in business development and advises pharma and biotech companies, investment banks and venture capitalists on issues such as partnering, M&A and strategic exits.
Following an early scientific career, Rogerson started in regulatory affairs and progressed to business development. He has been global head of pharmaceutical business development at Hoffmann-La Roche, head of corporate M&A for Novartis and md of Bear Stearns, leading its European Pharma M&A efforts.
Telormedix appoints new chairman
Nicholas Rogerson has taken the role
You may also like
Regulatory
![Early phase analytical strategy for biosimilars in a shifting regulatory landscape]()
Early phase analytical strategy for biosimilars in a shifting regulatory landscape
As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Pharmaceutical
![Formulation freedom in clinical development: Why Fill2Weight matters]()
Formulation freedom in clinical development: Why Fill2Weight matters
As drug discovery accelerates, especially for poorly soluble small‑molecule compounds, formulation teams increasingly modify particle size, morphology and structure to improve dissolution in the body. This is precisely where 3P innovation’s proprietary Fill2Weight Gravimetric Powder Filler becomes a game‑changer
Research & Development
![Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline]()
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline
The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period
Pharmaceutical
![Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate]()
Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate
The agreement will expand Teva’s biosimilars pipeline, with the company securing exclusive commercialisation rights for Polpharma Biologics’ proposed ocrelizumab biosimilar across key global markets
Pharmaceutical
![Pouching solutions for sterile and moisture-sensitive devices]()
Pouching solutions for sterile and moisture-sensitive devices
Sterile pouch loading and sealing is far more complex than a conventional packaging operation: When the pouch itself becomes the primary sterile barrier (and the product is filled aseptically) the packaging process must be engineered with the same level of care as the filling operation itself
